Septerna, Inc. (NASDAQ:SEPN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Septerna, Inc. (NASDAQ:SEPN) have been given a consensus rating of “Moderate Buy” by the eleven research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $52.4444.

SEPN has been the topic of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Friday, July 17th. Stifel Nicolaus set a $49.00 price objective on Septerna in a report on Tuesday, August 11th. JonesTrading lifted their target price on Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $49.00 target price on shares of Septerna in a research report on Tuesday, August 11th. Finally, HC Wainwright upped their target price on Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th.

Insiders Place Their Bets

In related news, insider Samira Shaikhly sold 11,798 shares of the firm’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total value of $354,647.88. Following the completion of the transaction, the insider directly owned 793 shares of the company’s stock, valued at approximately $23,837.58. This trade represents a 93.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Elizabeth Bhatt sold 25,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the transaction, the chief operating officer owned 174,209 shares in the company, valued at approximately $7,665,196. The trade was a 12.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 72,828 shares of company stock valued at $2,684,314 in the last 90 days. 5.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SEPN. Renaissance Technologies LLC bought a new stake in shares of Septerna in the 1st quarter valued at about $906,000. TRV GP VI LLC bought a new position in Septerna during the second quarter worth about $141,048,460,000. First Light Asset Management LLC grew its holdings in Septerna by 18.0% during the first quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock worth $17,611,000 after purchasing an additional 112,049 shares during the period. Janus Henderson Group PLC acquired a new position in Septerna during the first quarter worth approximately $21,334,000. Finally, TRV GP V LLC acquired a new position in Septerna during the second quarter worth approximately $208,160,143,000.

Septerna Stock Down 1.9%

NASDAQ SEPN opened at $40.00 on Friday. Septerna has a 12-month low of $11.70 and a 12-month high of $51.10. The company has a market capitalization of $1.87 billion, a PE ratio of -74.07 and a beta of 2.29. The firm’s 50 day moving average is $36.85 and its 200-day moving average is $30.28.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, August 10th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.14. The business had revenue of $26.75 million during the quarter, compared to analysts’ expectations of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. As a group, sell-side analysts expect that Septerna will post -1.36 EPS for the current year.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.